Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.27 | 3e-05 |
mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.29 | 0.0001 |
mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.2 | 0.0002 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.25 | 0.0003 |
mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.0003 |
mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.0005 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0005 |
mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0008 |
mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |